Vermont Business Times
SEE OTHER BRANDS

Fresh news on business and economy in Vermont

Vermont Business Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Business Times.

Press releases published on August 6, 2025

Oportun Achieves Third Straight Quarter of GAAP Profitability and Raises Full-Year 2025 Outlook

Oportun Achieves Third Straight Quarter of GAAP Profitability and Raises Full-Year 2025 Outlook

GAAP Net income of $6.9 million, a $38 million year-over-year improvement GAAP EPS of $0.14, a $0.92 year-over-year improvement Adjusted EPS of $0.31, up 288% versus prior-year quarter Operating expenses down 13% year-over-year, driving continued margin …

MediaAlpha Reaches Settlement with FTC

MediaAlpha Reaches Settlement with FTC

LOS ANGELES, Aug. 06, 2025 (GLOBE NEWSWIRE) -- MediaAlpha, Inc. (NYSE: MAX) ("MediaAlpha" or the "Company") today announced that it has reached a settlement with the Federal Trade Commission (“FTC”) to fully resolve matters related to the previously …

Ormat Technologies Reports Second Quarter 2025 Financial Results

Ormat Technologies Reports Second Quarter 2025 Financial Results

EXPANDED PORTFOLIO AND FAVORABLE OBBB POLICY SUPPORT LONG TERM GROWTH TARGETS HIGHLIGHTS NET INCOME AND ADJUSTED EBITDA GROWTH OF 26.1% AND 6.7%, RESPECTIVELY SUCCESSFUL COMPLETION OF 20MW BLUE MOUNTAIN GEOTHERMAL POWER PLANT ACQUISITION SECURED $300 …

SuRo Capital Corp. Reports Second Quarter 2025 Financial Results

SuRo Capital Corp. Reports Second Quarter 2025 Financial Results

Ongoing Net Asset Value Growth Driven by AI-Focused Investments Net Asset Value of $9.18 Per Share as of June 30, 2025 NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) …

Magnite Reports Second Quarter 2025 Results

Magnite Reports Second Quarter 2025 Results

Contribution ex-TAC(1) Grows 10% Year-Over-Year Contribution ex-TAC(1) from CTV Grows 14% Year-Over-Year NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Magnite (NASDAQ: MGNI), the largest independent sell-side advertising company, today reported its results …

GEN Restaurant Group Announces Second Quarter 2025 Financial Results

GEN Restaurant Group Announces Second Quarter 2025 Financial Results

CERRITOS, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- GEN Restaurant Group, Inc. (“GEN” or the “Company”) (Nasdaq: GENK), owner of GEN Korean BBQ, a fast-growing casual dining concept with an extensive menu and signature “grill at your table” experience, is …

Pennant Reports Second Quarter 2025 Results

Pennant Reports Second Quarter 2025 Results

EAGLE, Idaho, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted …

Upwork Reports Second Quarter 2025 Financial Results

Upwork Reports Second Quarter 2025 Financial Results

Achieves record second quarter with revenue of $194.9 million Generates GAAP net income of $32.7 million and adjusted EBITDA of $57.1 million, resulting in 17% profit margin and 29% adjusted EBITDA margin Raises FY2025 revenue and adjusted EBITDA guidance …

PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited …

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year  FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors …

Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second …

Green Thumb Industries Reports Second Quarter 2025 Results

Green Thumb Industries Reports Second Quarter 2025 Results

CHICAGO and VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, …

Voyager Reports Second Quarter 2025 Financial and Operating Results

Voyager Reports Second Quarter 2025 Financial and Operating Results

- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential for $2.6B in …

Capital Southwest Announces Financial Results for First Fiscal Quarter Ended June 30, 2025

Capital Southwest Announces Financial Results for First Fiscal Quarter Ended June 30, 2025

DALLAS, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the …

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …

Howard Hughes Holdings Inc. Reports Second Quarter 2025 Results

Howard Hughes Holdings Inc. Reports Second Quarter 2025 Results

THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Howard Hughes Holdings Inc. (NYSE: HHH) (the “Company,” “HHH,” “Howard Hughes,” or “we”) today announced operating results for the second quarter ended June 30, 2025. The financial statements, …

Duolingo Reports 41% Revenue Growth, 46% Subscription Revenue Growth and Record Profitability in Second Quarter 2025; Raises Full-Year Guidance

Duolingo Reports 41% Revenue Growth, 46% Subscription Revenue Growth and Record Profitability in Second Quarter 2025; Raises Full-Year Guidance

PITTSBURGH, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Duolingo, Inc. (NASDAQ: DUOL) announced results for the second quarter ended June 30, 2025 in a shareholder letter that is posted on its Investor Relations website at investors.duolingo.com. “We exceeded our …

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results

REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase …

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Keros Therapeutics Reports Second Quarter 2025 Financial Results

LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions